Among the various routes of drug delivery, the oral route is perhaps one of the most studied and preferred by patients and clinicians. About 70% of drugs are administered orally, primarily in tablet or capsule form however, there are a number of disadvantages associated with oral administration such as hepatic first-pass metabolism and enzymatic degradation within the gastrointestinal (GI) tract, which cause a relatively lengthy onset time and/or erratic absorption patterns. Furthermore, patients must be conscious and able to swallow (40% of US adults and 54% of children (6-11 years) report swallowing difficulties) and in most cases need to have access to drinking water.

The oral mucosa is the moist epithelial lining of the oral cavity, which includes the tongue, cheeks, palate and gums. Drug delivery within the oral mucosal cavity is classified into five categories:

  1. local delivery, which is drug delivery into the oral cavity;
  2. sublingual delivery, which is systemic delivery of drugs through the mucosal membranes lining the floor of the mouth;
  3. buccal delivery, which is drug administration through the mucosal membranes lining the cheeks (buccal mucosa);
  4. lingual delivery is drug administration on the tongue; and
  5. gingival delivery is drug administration through the gums.


SUDA is utilising its delivery technology to reformulate well-characterised molecules with known and proven regulatory routes to develop innovative patentable products, which provide a solution to a current market need.